Nl-Fr

View abstract

This abstract is assigned to session Free Papers : Posters on Display - Series 101-1..
Presentation preference Poster presentation
TitlePersistent Ocular Herpes Zoster Confirmed by PCR in a Young Patient with Multiple Sclerosis on Dimethyl Fumarate Therapy
Accept poster if oral is not possible ?Yes
PurposeTo report the case of a patient with multiple sclerosis (MS) on dimethyl fumarate (DMF) treatment who developed herpes zoster ophthalmicus (HZO), leading to recurrent stromal keratitis and uveitis, and to describe the cessation of recurrences following the administration of the Shingrix vaccine.
MethodsCase Report
ResultsA 38-year-old female with a history of MS and optic neuritis, treated with DMF, presented with HZO. The patient was managed with high dose valaciclovir (3g daily for 6 months), topical corticosteroids, and losartan eye drops, which improved stromal opacities. Despite ongoing antiviral and steroid therapy, the patient experienced multiple recurrences of keratouveitis and stromal scarring. Ocular PCR testing six months after the initial manifestation was positive for herpes type 3. After stabilization of the acute episodes, the recombinant zoster vaccine (RZV, Shingrix) was administered. Post-vaccination, the patient reported no further recurrences of herpes zoster or its ocular manifestations. The use of losartan eye drops was effective in reducing corneal stromal opacities.
ConclusionThis case underscores the necessity of vaccination with the recombinant zoster vaccine (RZV) in immunosuppressed patients. The American Academy of Ophthalmology recommend RZV for immunocompromised adults aged 18 and older, affirming its critical role in protecting this vulnerable population. Additionally, the use of losartan eye drops has proven beneficial in managing stromal keratitis in such complex cases. Moreover, there is a need for further studies to determine the optimal timing and safety of Shingrix administration specifically within the field of ophthalmology.
Conflict of interestYes
Details of conflicting interestsI declare that I am a speaker for GSK, the manufacturer of the Shingrix vaccine.
1
Last namePEIXOTO DOS SANTOS FINAMOR
Initials of first name(s)L
DepartmentOphthalmology department - Federal University of São Paulo ; Clínica Moacir Cunha/grupo Fleury
CitySão Paulo
CountryBrazil
2
Last nameCunha
Initials of first name(s)L
DepartmentClinica de Olhos Dr. Moacir Cunha/Grupo Fleury
CitySão Paulo
CountryBrazil
3
Last nameLazary
Initials of first name(s)C
DepartmentGrupo Fleury
CitySão Paulo
CountryBrazil
4
Last nameAndrade
Initials of first name(s)G
DepartmentClínica de Olhos Dr. Moacir Cunha/Grupo Fleury
CitySão Paulo
CountryBrazil
5
Last nameZanetti
Initials of first name(s)B
DepartmentClínica de Olhos Dr. Moacir Cunha/Grupo Fleury
CitySão Paulo
CountryBrazil
6
Last nameGranato
Initials of first name(s)C
DepartmentDepartment of Infectious Disease UNIFESP; Grupo Fleury
CitySão Paulo
CountryBrazil